Related Experiment Video
Updated: Aug 9, 2026
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
The effect of PGA1 on the immune response in B-16 melanoma-bearing mice
Abstract:
This study evaluated the effects of PGA1 on B-16 melanoma-bearing mice. Intraperitoneal injection of PGA1 (10 microgram/day) significantly inhibited the rate of melanoma growth measured both as delay in the rate of appearance and decrease in the tumor volume. In contrast to the diluent control-treated mice, by 17 days, less than half of the PGA1-treated animals developed measurable (greater than 2 mm) subcutaneous tumors. In addition to its effect on tumor size, PGA1 was also effective in stimulating both the humoral and cellular components of the immune response. B-16 tumor-bearing mice were shown to be immunosuppressed, in that they had decreased anti-sRBC hemagglutinin titers, decreased splenic plaque-forming cells, suppressed delayed hypersensitivity responses, and delayed rejection of skin allografts from BALB/c mice. Although, PGA1 had relatively little effect on normal mice, this prostaglandin substantially improved all these immunologic parameters in tumor-bearing animals.
Insights
Prostaglandin A1 (PGA1) significantly inhibited melanoma growth and boosted immune responses in mice with B-16 melanoma. PGA1 treatment improved immune parameters in tumor-bearing mice without affecting normal mice.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- B-16 melanoma in mice exhibits immunosuppression, characterized by reduced antibody titers, B-cell activity, delayed hypersensitivity, and skin graft rejection.
- Prostaglandins are known modulators of immune responses, but their specific effects on melanoma-induced immunosuppression require further investigation.
Purpose of the Study:
- To evaluate the therapeutic potential of Prostaglandin A1 (PGA1) in inhibiting B-16 melanoma growth.
- To investigate the impact of PGA1 on both humoral and cellular immune responses in tumor-bearing mice.
Main Methods:
- B-16 melanoma-bearing mice were treated with intraperitoneal injections of PGA1 (10 microgram/day).
- Tumor growth was monitored by measuring the rate of appearance and tumor volume.
- Humoral immunity was assessed via anti-sRBC hemagglutinin titers and splenic plaque-forming cells.
- Cellular immunity was evaluated through delayed hypersensitivity responses and skin allograft rejection assays.
Main Results:
- PGA1 administration significantly inhibited melanoma growth, delaying tumor appearance and reducing tumor volume.
- By day 17, less than 50% of PGA1-treated mice developed measurable tumors compared to controls.
- PGA1 treatment substantially improved all measured immunologic parameters in tumor-bearing mice, restoring them towards normal levels.
- PGA1 showed minimal effects on immune parameters in normal, non-tumor-bearing mice.
Conclusions:
- Prostaglandin A1 (PGA1) demonstrates significant anti-tumor activity against B-16 melanoma in mice.
- PGA1 effectively counteracts the immunosuppression associated with B-16 melanoma, enhancing both humoral and cellular immunity.
- These findings suggest PGA1 as a potential immunomodulatory agent for cancer therapy.
